{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-091856","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.931039+00:00","generated_at":"2026-06-26T12:42:13.724737+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech reports FY2021 net loss of $67.9M; cash of $211.5M supports operations into mid-2024","bullets":["Net loss $67.9M in FY2021 vs $12.0M in FY2020; R&D expenses rose to $30.2M from $8.5M.","Cash and cash equivalents of $211.5M at Dec 31, 2021; expected runway through multiple data readouts into mid-2024.","Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 + KEYTRUDA in advanced melanoma began patient recruitment.","Updated Phase 1/2 data (MM1636) in metastatic melanoma to be presented at AACR 2022.","Management notes longer-than-expected lead times in clinical site activation and patient enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-091856","json":"https://secwatch.observer/filing/0001193125-22-091856.json","markdown":"https://secwatch.observer/filing/0001193125-22-091856.md","text":"https://secwatch.observer/filing/0001193125-22-091856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/0001193125-22-091856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/d342643d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:42:13.724737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}